Jill Fiedler-Kelly, Vice President, Pharmacometric Services was awarded fellow status in the International Society of Pharmacometricians at the 7th Annual American Conference of Pharmacometricians in Bellevue, Washington, along with her esteemed colleagues: Dr. Bill Jusko, Distinguished Professor of Pharmaceutical Sciences at University at Buffalo, Dr. Matts Karlson, Professor, Pharmaceutical Biosciences at University of Uppsala; and Dr. Nick Holford, Professor, Clinical Pharamcology, University of Auckland.

Two posters presented at the 169th Annual Meeting of the American Psychiatric Association (APA), May 14-18, 2016; Atlanta, Georgia by our colleagues at Allergan along with Cognigen authors and their collective expertise in the area of psychotherapeutic agents. The pharmacokinetics of cariprazine and its major metabolites were characterized utilizing a population approach of pooling pharmacokinetic data from 13 studies. Further exposure-response relationships were presented in subjects with schizophrenia or bipolar disorder. See here for the PK poster. See here for the PK/PD poster.

A poster presented at the American Thoracic Society (ATS) International Congress, May 13–18, 2016, San Francisco, CA USA by our colleagues at Teva along with Cognigen authors and their collective expertise in the area of pulmonary disease. Pharmacokinetic modeling and simulations were used to support weight-based dosing for intravenous reslizumab.See the poster here.

A poster presented at the American Academy of Neurology (AAN) Annual Meeting, April 15–21 2016, Vancouver, BC, Canada by our colleagues at Sunovion along with Cognigen authors and their collective expertise in the area of epilepsy. Pharmacokinetic-pharmacodynamic modeling and simulations were used to predict efficacy outcomes with eslicarbazepine acetate 800 mg once daily as monotherapy . See the poster here.

Harness the power of pharmacometrics.

Raise your hand if you wish there was a way to make drug development more efficient. Guess what? There is. It’s called model-based drug development, and it involves using quantitative analysis to better design protocols, determine dosage levels, and figure out other neat stuff that lead to successful regulatory filings. Once you see how incredible (and cost-effective) pharmacometrics can be, you’ll be hooked.